Table 8.
Odds ratios (ORs) and 95% confidence intervals (CIs) for 2011 baseline SUA associated with the incidence of T2DM in 2015.
| N = 5,479 | Model 1 OR (95% CI) | Wald, df | p | Model 2 OR (95% CI) | Wald, df | p | Model 3 OR (95% CI) | Wald, df | p | Model 4 OR (95% CI) | Wald, df | p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (N = 2,478) | ||||||||||||
| Q1 (619) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (620) | 0.978 (0.696,1.374) | 0.0171 | 0.897 | 0.968 (0.689,1.362) | 0.0341 | 0.854 | 0.963 (0.684,1.355) | 0.0481 | 0.827 | 0.904 (0.641,1.276) | 0.3291 | 0.566 |
| Q3 (620) | 0.983 (0.699,1.382) | 0.0091 | 0.922 | 0.967 (0.687,1.361) | 0.0371 | 0.848 | 0.981 (0.696,1.384) | 0.0111 | 0.915 | 0.902 (0.637,1.277) | 0.3381 | 0.561 |
| Q4 (619) | 1.213 (0.874,1.684) | 1.3351 | 0.248 | 1.178 (0.847,1.639) | 0.9451 | 0.331 | 1.197 (0.859,1.669) | 1.1271 | 0.288 | 1.062 (0.757,1.488) | 0.1211 | 0.728 |
| P-trend | 1.063 (0.956,1.182) | 1.2801 | 0.258 | 1.053 (0.946,1.171) | 0.8971 | 0.344 | 1.060 (0.952,1.180) | 1.1431 | 0.285 | 1.021 (0.915,1.139) | 0.1391 | 0.709 |
| Female (N = 3,001) | ||||||||||||
| Q1 (749) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (752) | 1.213 (0.861,1.708) | 1.2171 | 0.270 | 1.190 (0.844,1.678) | 0.9861 | 0.321 | 1.187 (0.841,1.675) | 0.9511 | 0.329 | 1.128 (0.797,1.595) | 0.4621 | 0.497 |
| Q3 (750) | 1.577 (1.137,2.189) | 7.4421 | 0.006 | 1.523 (1.095,2.117) | 6.2621 | 0.012 | 1.504 (1.081,2.092) | 5.8571 | 0.016 | 1.370 (0.981,1.913) | 3.4091 | 0.065 |
| Q4 (750) | 2.231 (1.631,3.050) | 25.2711 | 0.000 | 2.090 (1.523,2.867) | 20.8781 | 0.000 | 2.075 (1.511,2.849) | 20.3531 | 0.000 | 1.707 (1.234,2.362) | 10.4361 | 0.001 |
| P-trend | 1.314 (1.191,1.450) | 29.4371 | 0.000 | 1.286 (1.164,1.420) | 24.4021 | 0.000 | 1.282 (1.160,1.417) | 23.6811 | 0.000 | 1.201 (1.085,1.331) | 12.3691 | 0.000 |
| Total (N = 5,479) | ||||||||||||
| Q1 (1371) | Ref (1.000) | Ref (1.000) | Ref (1.000) | Ref (1.000) | ||||||||
| Q2 (1375) | 1.155 (0.910,1.466) | 1.4051 | 0.236 | 1.127 (0.887,1.431) | 0.9591 | 0.328 | 1.142 (0.898,1.451) | 1.171 | 0.279 | 1.090 (0.856,1.388) | 0.4881 | 0.485 |
| Q3 (1365) | 1.263 (0.998,1.597) | 3.7921 | 0.051 | 1.211 (0.955,1.535) | 2.4941 | 0.114 | 1.247 (0.981,1.586) | 3.2491 | 0.071 | 1.117 (0.876,1.424) | 0.7961 | 0.372 |
| Q4 (1368) | 1.601 (1.277,2.008) | 16.6341 | 0.000 | 1.519 (1.204,1.915) | 12.4651 | 0.000 | 1.597 (1.257,2.027) | 14.7391 | 0.000 | 1.380 (1.083,1.760) | 6.7651 | 0.009 |
| P-trend | 1.165 (1.084,1.251) | 17.3841 | 0.000 | 1.175 (1.086,1.271) | 16.1671 | 0.000 | 1.177 (1.088,1.274) | 16.4771 | 0.000 | 1.112 (1.026,1.205) | 6.7161 | 0.010 |
ORs, odds ratios; CIs, confidence intervals; SUA, serum uric acid; T2DM, type 2 diabetes mellitus; BMI, body mass index.
Model 1: unadjusted.
Model 2: adjusted for age, sex (total subgroup), education level, marital status, and current residence.
Model 3: adjusted for age, sex (total subgroup), education level, marital status, current residence, smoking status, alcohol consumption, social interaction, physical activity, and chronic disease.
Model 4: adjusted for age, sex (total subgroup), education level, marital status, current residence, smoking status, alcohol consumption, social interaction, physical activity, chronic disease, and BMI.
The cutoff values of baseline SUA in males: <4.054 mg/dL, 4.054 to < 4.758 mg/dL, 4.758 to < 5.625 mg/dL, ≥5.625 mg/dL.
The cutoff values of baseline SUA in females: <3.241 mg/dL, 3.241 to < 3.812 mg/dL, 3.812 to < 4.499 mg/dL, ≥4.499 mg/dL.
The cutoff values of baseline SUA in total participants: <3.524 mg/dL, 3.524 to < 4.224 mg/dL, 4.224 to < 5.055 mg/dL, ≥5.055 mg/dL.